Clinical Trials

A Global Randomized Multicenter Phase 3 Trial To Compare The Efficacy And Safety Of Jcar017 To Standard Of Care In Adult Subjects With High-Risk, Transplanteligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform)


Study ID
Juno Therapeutics-JCAR017-BCM-003

NCT Number
NCT03575351 (Click on the NCT number for more information about the trial)

Research Study Number
2018-1034

Principle Investigator
Dr. Tatyana Feldman

Phase
III

Sponsor
Juno Thereapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now